Archives of Medical Research
Volume 40, Issue 7 , Pages 595-599 , October 2009

Expression of Prostate Apoptosis Response (Par-4) Is Associated with Progesterone Receptor in Breast Cancer

  • Pablo Zapata-Benavides

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México
    • ,
  • José L. Méndez-Vázquez

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México
    • ,
  • Talina R. González-Rocha

      Affiliations

    • Laboratorio de Anatomía Patológica, Hospital Christus Muguerza, Monterrey, Nuevo León, México
    • ,
  • Diana E. Zamora-Avila

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México
    • ,
  • Moises A. Franco-Molina

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México
    • ,
  • Raúl Garza-Garza

      Affiliations

    • Laboratorio de Anatomía Patológica, Hospital Christus Muguerza, Monterrey, Nuevo León, México
    • ,
  • Cristina Rodriguez-Padilla

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México
    • Corresponding Author InformationAddress reprint requests to: Cristina Rodriguez-Padilla, Pedro de Alba S/N, San Nicolás de los Garza, 66450 Nuevo León, México; FAX: (+52) (81) 8352-4212

Received 24 October 2008 ,Accepted 31 July 2009.

References 

  1. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful?. Clin Biochem. 2001;34:347–352
  2. Kariya S, Ogawa Y, Nishioka A, et al. Relationship between hormonal receptors, HER-2, p53 Protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med. 2005;23:189–194
  3. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000;2751:2751–2758
  4. Kröger N, Milde-Langosch K, Riethdorf S, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006;2:159–168
  5. Choi HD, Kim S, Rimm LD, et al. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005;11:404–411
  6. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25:4772–4778
  7. Murphy G, Muss HB. Hormonal therapy of breast cancer: state of the art. Oncology. 1997;11:7–13
  8. De Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002;8(4 suppl):S19–S26
  9. Sells SF, Wood DP, Joshi-Barve SS, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and-independent prostate cells. Cell Growth Differ. 1994;5:457–466
  10. Sells SF, Han SS, Muthukkumar S, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol. 1997;17:3823–3832
  11. Chendil D, Das A, Dey S, et al. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther. 2002;1:152–160
  12. Chan SL, Tammariello SP, Estus S, et al. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J Neurochem. 1999;73:502–512
  13. Chakraborty M, Qiu SG, Vasudevan KM, et al. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 2001;61:7255–7263
  14. Qiu G, Ahmed M, Sells SF, et al. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene. 1999;18:623–631
  15. Barradas M, Monjas A, Diaz-Meco MT, et al. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J. 1999;18:6362–6369
  16. Garcia-Cao I, Duran A, Collado M, et al. Tumour suppression activity of the proapoptotic regulator Par4. EMBO Rep. 2005;6:577–583
  17. Cook J, Krishnan S, Ananth S, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene. 1999;18:1205–1208
  18. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 2007;67:1927–1934
  19. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750
  20. Wang L, Jiang Z, Sui M, et al. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 2009;11(9):226
  21. De Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–1513
  22. Gurumurthy S, Rangnekar VM. Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem. 2004;91:504–512
  23. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979
  24. Bernoux A, De Cremoux P, Lainé-Bridon C, et al. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat. 1998;49:219–225
  25. Gao S, Wang H, Lee P, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol. 2006;36:463–483
  26. Azmi AS, Wang Z, Burikhanov R, et al. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther. 2008;7:2884–2893
  27. Lee JW, Lee KF, Hsu HY, et al. Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Lett. 2007;257:252–262
  28. Cheema SK, Mishra SK, Rangnekar VM, et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem. 2003;278:19995–20005
  29. El-Guendy N, Zhao Y, Gurumurthy S, et al. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol. 2003;23:5516–5525
  30. Ranganathan P, Rangnekar VM. Regulation of cancer cell survival by Par-4. Ann NY Acad Sci. 2005;1059:76–85
  31. Pruitt K, Ulkü AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem. 2005;280:23363–23370

PII: S0188-4409(09)00149-0

doi: 10.1016/j.arcmed.2009.08.007

Archives of Medical Research
Volume 40, Issue 7 , Pages 595-599 , October 2009

Article Tools

* Image Usage & Resolution